NASDAQ: MGRXMangoceuticals Inc Stock
$0.33+0.00 (+0%)
Updated Jun 17, 2026
MGRX Price
$0.33
Fair Value Price
-$0.29
Market Cap
$5.70M
52 Week Low
$0.16
52 Week High
$2.75
P/E
-0.22x
P/B
0.42x
P/S
14.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$414.58k
Earnings
-$19.21M
Gross Margin
52.4%
Operating Margin
-4,604.56%
Profit Margin
-4,845.6%
Debt to Equity
0.07
Operating Cash Flow
-$5M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGRX Overview
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MGRX's potential to beat the market
- MGRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
C
MGRX
RankedUnranked of 44
RankedUnranked of 44
Be the first to know about important MGRX news, forecast changes, insider trades & much more!
MGRX News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGRX ($0.33) is overvalued by 213.4% relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MGRX ($0.33) is not significantly undervalued (213.4%) relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MGRX due diligence checks available for Premium users.
Valuation
MGRX fair value
Fair Value of MGRX stock based on Discounted Cash Flow (DCF)
Price
$0.33
Fair Value
-$0.29
Undervalued by
212.72%
MGRX ($0.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MGRX ($0.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
13.92x
Market
12.4x
MGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
3.02x
MGRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGRX's financial health
Profit margin
Revenue
$67.9k
Net Income
-$3.4M
Profit Margin
-5,447.9%
MGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.4M
Liabilities
$974.6k
Debt to equity
0.07
MGRX's short-term liabilities ($737.61k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGRX's long-term liabilities ($236.97k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$0.0
Financing
$0.0
MGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGRX vs Health Information Service Stocks
Mangoceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.